New Alzheimer's Drug Shows Promise as Monotherapy

Research Report
  ()
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report.

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression

Research Report
  ()
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report.
Tags:  Psychedelics

Approval Likely of New Gel for Skin Condition, Analyst Says

Research Report
  ()
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.

Results of Dermatitis Clinical Trial Due This Summer

Research Report
  ()
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.

New Positive Data Seem to Support Drug Label Expansion

Research Report
  ()
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.

New Drug for Heart Failure on Path to Approval, Analyst Says

Research Report
  ()
The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.

Biotech Co. Advances 3 New Clinical Stage Assets

Research Report
  ()
Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

Research Report
  ()
The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.

Expert Investing Ideas

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


"AGN's current valuation is favorable from a risk-reward standpoint."

–André Uddin, Research Capital Corporation


"We could soon see some good gains in AGN."

–Clive Maund, CliveMaund.com


"AGN's risk/reward profile is attractive."

–André Uddin, Research Capital Corporation


"AGN is switching focus to the IPF/chronic cough indication."

–André Uddin, Research Capital Corporation


"AGN requested a meeting with the FDA to discuss advancing ifenprodil."

–André Uddin, Research Capital Corporation


"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

–André Uddin, Research Capital Corporation


"AGN is to continue a number of preclinical studies of DMT for stroke."

–André Uddin, Research Capital Corporation


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22

Research Report
  ()
These changes earned Reliq Health Technologies Inc. an upgrade in overall rating by independent investment research and advisory firm, Jefferson Research.

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

Research Report
  ()
The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

Research Report
  ()
Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Research Report
  ()
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.